IP Library Granted Patent US 10,772,973
Granted Patent B2
US 10,772,973 · App. 15/991,033 · Granted Sep 15, 2020

Targeted shell for use in drug delivery system utilizing carbosilane dendrimer

Inventors: Miho Suzuki (Saitama, JP); Ken Hatano (Saitama, JP); Shojiro Yoshida (Saitama, JP); Yasuhiro Yamashita (Tokyo, JP)
Assignees: QUARRYMEN & Co. Inc.; Saitama University
A61K47/6941A61K47/24A61K47/42A61K47/56A61K47/59A61K47/6425A61K47/66A61K47/6907A61K47/6925A61K47/6931A61K49/00A61K49/0045C07K14/43509C07K14/43595C07K17/00C08G83/003A61P35/00A61P37/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,772,973
App. No.
15/991,033
Granted
Sep 15, 2020
Kind
B2
Abstract

The present invention is related to a targeted type shell for drug delivery system. The object of the present invention is to provide the targeted type shell for DDS, which comprises a carbosilane dendrimer containing a silole produced by which is formed by utilizing the reaction between thiol group and alkyl halide, and a targeted protein containing a labeled proteins such as green fluorescent protein with a target recognition site. The shell may incorporate compounds having a variety of molecular weight and biopolymers, and selectively deliver them into targeted cells.

Claims (47)

1. A targeted type shell for drug delivery system comprising an aggregatable molecule shown in formula (I):

wherein,

each Y independently represents a bromine atom, a sulfur atom, or a target sequence presented,

wherein:

at least one Y is the target sequence presented part and is bound through a sulfur atom,

the target sequence presented part is composed of a protein or peptide having a target recognition site, and

provided that at least one Y is not bromine;

wherein the targeted type shell for drug delivery system encloses any molecule selected from the group consisting of a protein having molecular weight of 200,000 or less, a nucleic acid and a hydrophobic molecule.

2. The targeted type shell for drug delivery system according to the claim 1 , wherein said peptide specifically binds to any targeted protein selected from the group consisting of a surface antigen, a receptor, a gate, a transporter and a channel to form a conjugate for promoting endocytosis of said conjugate into a cell.

3. The targeted type shell for drug delivery system according to the claim 1 , wherein said peptide comprises the amino acid sequence selected from the group consisting of:

DMPGTVLPGG

(Sequence No. 1 in the sequence listing);

VPTDTDYSGG

(Sequence No. 2 in the sequence listing);

and

DMPGTVLPGG GGGSEGEWQ QQQHQWAKQE 

(Sequence No. 3 in the sequence listing).

4. The targeted type shell for drug delivery system according to the claim 1 , wherein said peptide comprises the amino acid sequence selected from the group consisting of:

MASMTGGQQMGR DMPGTVLPGG MSKGEELFTG VVPILVELDG

DVNGHKFSVS GEGEGDATYG KLTLKFISTT GKLPVPWPTL

VTTLTYGVQC FSRYPDHMKR HDFFKSAMPE GYVQERTISF

KDDGNYKTRA EVKFEGDTLV NRIELKGIDF KEDGNILGHK

LEYNYNSHNV YITADKQRNG IKANFKTRHN IEDGSVQLAD

HYQQNTPIGD GPVLLPDNHY LSTQSALLKD PNEKRDHMVL

LEFVTAAGSGIT DEVDGT ELYK GG HHHHHH 

(Sequence No. 4 in the sequence listing);

MASMTGGQQMGR VPTDTDYSGG MSKGEELFTG VVPILVELDG

DVNGHKFSVS GEGEGDATYG KLTLKFISTT GKLPVPWPTL

VTTLTYGVQC FSRYPDHMKR HDFFKSAMPE GYVQERTISF

NDDGNYKTRA EVKFEGDTLV NRIELKGIDF KEDGNILGHK

LEYNYNSHNV YITADKQRNG IKANFKTRHN IEDGSVQLAD

HYQQNTPIGD GPVLLPDNHY LSTQSALLKD PNDKRDHMVL

LEFVTAAGSGIT DEVDGT ELYK GG HHHHHH 

(Sequence No. 5 in the sequence listing);

and

MASMTGGQQMGR DMPGTVLPGG GGGSEGEWQQQQHQWAKQE

MSKGEELFTG VVPILVELDG DVNGHKFSVS GEGEGDATYG

KLTLKFISTT GKLPVPWPTL VTTLTYGVQC FSRYPDHMKR

HDFFKSAMPE GYVQERTISF KDDGNYKTRA EVKFEGDTLV

NRIELKGIDF KEDGNILGHK LEYNYNSHNV YITADKQRNG

IKANFKTRHN IEDGSVQLAD HYQQNTPIGD GPVLLPDNHY

LSTQSALLKD PNEKRDHMVL LEFVTAAGSGIT DEVDGTC ELYK GG

HHHHHH

(Sequence No. 6 in the sequence listing).

5. The targeted type shell for drug delivery system according to claim 1 , wherein the target sequence presented part is composed of a protein or peptide having a target recognition site thereby being delivered to a. targeted tissue, wherein said. targeted tissue is any tissue selected from the group consisting of a normal tissue having inflammation, a tissue having undesirable gene expressions, a cell having undesirable gene expressions, and a tissue composed of tumor cells.

6. The targeted type shell for drug delivery system according to claim 1 , wherein said aggregatable molecule shown in the formula (I) is selected from the group consisting of the following formula (II) to (V), wherein TSPP in the formula means fluorescent protein with said target recognition site:

7. The targeted type shell for drug delivery system according to claim 6 , wherein said protein is any fluorescent protein selected from the group consisting of a red fluorescent protein, a yellow fluorescent protein, a blue fluorescent protein and a green fluorescent protein.

Assignments (2)
CHANGE OF NAME Recorded Jun 8, 2023
From: QUARRYMEN&CO. INC.
To: CYSAY INC.
Reel/Frame 063928/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: SUZUKI, MIHO; HATANO, KEN; YAMASHITA, YASUHIRO
To: QUARRYMEN&CO. INC.; SAITAMA UNIVERSITY
Reel/Frame 046813/0560 →
Priority Claims (1)
JP 2016-106700 · May 27, 2016 · national
Continuity (2)
Continuation PCTJP2016085604 · Nov 30, 2016
Related Publication 20180362718A1 · Dec 20, 2018